# Study of Busulfan for Refractory Central Nervous System (CNS) Tumors

> **NCT00836628** · PHASE1 · WITHDRAWN · sponsor: **Ann & Robert H Lurie Children's Hospital of Chicago**

## Conditions studied

- Refractory Brain Tumors

## Interventions

- **DRUG:** Busulfan

## Key facts

- **NCT ID:** NCT00836628
- **Lead sponsor:** Ann & Robert H Lurie Children's Hospital of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-07
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2020-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00836628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00836628, "Study of Busulfan for Refractory Central Nervous System (CNS) Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00836628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*